Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;22(2):794.
doi: 10.3892/etm.2021.10226. Epub 2021 May 25.

Effects of Salvia miltiorrhiza extract on lung adenocarcinoma

Affiliations

Effects of Salvia miltiorrhiza extract on lung adenocarcinoma

Huixiang Tian et al. Exp Ther Med. 2021 Aug.

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung carcinoma. Tanshinone I is an important fat-soluble component in the extract of Salvia miltiorrhiza that has been reported to inhibit lung adenocarcinoma cell proliferation. However, no studies have clearly demonstrated changes in lung adenocarcinoma gene expression and signaling pathway enrichment following Tanshinone I treatment. And it remains unclear whether salvianolate has an effect on lung adenocarcinoma. The present study downloaded the GSE9315 dataset from the Gene Expression Omnibus database to identify differentially expressed genes (DEGs) and the underlying signaling pathways involved after Tanshinone I administration in the lung adenocarcinoma cell line CL1-5. The results revealed that there were 28 and 102 DEGs in the low dosage group (0.01 and 0.10 µg/ml Tanshinone I) and medium dosage groups (1 and 10 µg/ml Tanshinone I), respectively. In the low dosage group, DEGs were mainly enriched in 'positive regulation of T-helper cell differentiation' and 'protein complex'. In the medium dosage group, 102 DEGs were enriched in 'MAPK cascade' and 'extracellular exosome'. Kyoto Encyclopedia of Genes and Genomes pathway analysis demonstrated enrichment of both groups in the PI3K-Akt signaling pathway. Furthermore, there were nine overlapping DEGs [ADP ribosylation factor-interacting protein 2, chemokine (C-X-C motif) ligand 6, SH2 domain-containing adaptor protein B, Src homology 2 domain-containing transforming protein1, collagen type VI α1 chain, elastin, integrin subunit α, endoplasmic reticulum mannosyl-oligosaccharide 1,2-α-mannosidase and sterile α motif domain-containing 9 like] between the two groups, which serve to be potential targets for the treatment of lung adenocarcinoma. The present study also investigated the possible effects of salvianolate on lung adenocarcinoma in vivo using nude mouse xenograft models injected with the A549 cell line. The data revealed that salvianolate not only suppressed lung adenocarcinoma tumor growth of in nude mice, but also downregulated the expression levels of ATP7A and ATP7B, which are important proteins in the tumorigenesis and chemotherapy of lung adenocarcinoma. The present study provided evidence for the potential use of Salvia miltiorrhiza extract for treating lung adenocarcinomas in the clinic.

Keywords: anticancer effect; differentially expressed genes; lung adenocarcinoma; salvianolate; tanshinone I.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Venn diagram and heatmaps of DEGs in the different groups. (A) Venn diagram shows that there were nine overlapping DEGs in the low and middle dosage group, which contains 19 and 93 DEGs, respectively. Heatmap of DEGs (B) in the low dosage and (C) the medium dosage group. (D) Heatmap of the overlapping DEGs in the low and medium dosage groups. Red and green represent up- and downregulation of gene expression, respectively. DEGs, differentially expressed genes; Tan I, tanshinone I.
Figure 2
Figure 2
GO and KEGG pathway enrichment analysis in the low and medium dosage groups. GO enrichment analysis in the (A) low dosage and (B) medium dosage groups, and KEGG pathway enrichment analysis in the (C) low dosage and (D) medium dosage groups were performed using Database for Annotation, Visualization and Integrated Discovery, before being visualized using RStudio. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 3
Figure 3
PPI network and module analysis in the different dosage groups. PPI network of differentially expressed genes in the (A) low dosage and (B) medium dosage group were constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins database. (C) A key module in the low dosage group and (D) two modules in the medium dosage group were identified using MCODE in the Cytoscape software. PPI, protein-protein interaction.
Figure 4
Figure 4
Salvianolate suppresses lung carcinoma xenograft tumor growth. (A) Compared with the control group, salvianolate significantly restricted the growth of tumors 10, 13 and 16 days. (B) All three dosages of salvianolate increased the tumor inhibition rate, among which salvianolate (50 mg/kg) conferred the highest inhibition rate. (C) The tumor sections in the various groups were analyzed using hematoxylin and eosin staining (magnification, x400). Red arrows indicate nuclear pyknosis and fragmentation. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001 vs. Control group.
Figure 5
Figure 5
Expression levels of ATP7A and ATP7B are decreased following salvianolate administration. (A) Representative images of immunohistochemical staining for ATP7A and ATP7B expression on tumor tissues from the nude mice (magnification, x400). (B) Integral optical densities of ATP7A and ATP7B were analyzed. *P<0.05 and **P<0.01. ATP7, ATPase copper transporting.

Similar articles

Cited by

References

    1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(85) doi: 10.5334/aogh.2419. - DOI - PMC - PubMed
    1. World Health Organization: Cancer Today. 2021. Accessed from https://gco.iarc.fr/today/home.
    1. Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(7) doi: 10.1098/rsob.170070. - DOI - PMC - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454. doi: 10.1038/nature25183. - DOI - PubMed
    1. Zhou K, Zhao S, Guo W, Ding L. Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99(e18771) doi: 10.1097/MD.0000000000018771. - DOI - PMC - PubMed

Grants and funding

Funding: The present study was financially supported by the Hunan Provincial Natural Science Foundation of China (grant no. 2019JJ40519) and Hunan Province Traditional Chinese Medicine Research Project (grant no. 201179).